To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation
Provider Data DescriptionNCT00866918-D2
These data provide specific incidence of adverse events in interest. This dataset is necessary to construct Table 3 (Toxicities Reported in >10% of Patients During a Course of Therapy) on the manuscript.
SponsorNational Cancer Institute
Data ProviderNational Cancer Institute
Partial set or SubsetN/A
Patients in dataset525
# of Patients Control261
# of Patients Experimental261
Clinical Trials.gov Information
Brief SummaryThis phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
ConditionsChildhood Acute Promyelocytic Leukemia (M3) Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies